What are the latest funding news in the longevity market? (June 2026)
Download our beautiful pitch about the longevity market
In our longevity market deck, you will find everything you need to understand the market
Longevity funding remained very active in the first half of 2026, with large biotech rounds sitting next to smaller clinic, diagnostics, and software deals.
The latest qualifying rounds show that the longevity market is no longer only about supplements or wellness, because investors are also backing cellular reprogramming, stem-cell rejuvenation, mTOR biology, and clinic infrastructure.
NewLimit was the standout deal, but the broader pattern is a market that is moving from early science into clinical trials, regulated products, and service models with real customers.
And if you want to better understand this new industry, you can download our pitch covering the longevity market.
Insights
- Therapeutics dominated the money raised, with NewLimit, Life Biosciences, Loyal, Aeovian, Junevity, and HexemBio representing more than $690M of disclosed longevity market funding.
- The largest rounds went to companies with regulated drug paths, which suggests investors still see the biggest longevity outcomes in clinical products, not only consumer healthspan services.
- Clinic and diagnostic models raised smaller rounds, but TMRW, Biopeak, GlycanAge, Decode Age, and Ultralight show growing demand for practical longevity infrastructure.
- Cellular reprogramming remained one of the clearest investor themes, with NewLimit, Life Biosciences, and Junevity all raising around age-related cell function.
- Geographic activity was wider than the US biotech market, with Australia, India, the UK, Europe, and the MENA region all represented in recent longevity funding.
- Pet longevity is becoming investable on its own, because Loyal’s $100M Series C shows that lifespan extension can reach regulated animal health before human markets.
- Most companies did not disclose valuations, but NewLimit’s reported $3.1B valuation shows how scarce and valuable top-tier longevity therapeutics platforms have become.
- Several rounds were raised to move from research into execution, especially clinical trials, FDA review, IND-enabling work, manufacturing scale-up, and clinic expansion.
As this slide shows, and as featured in our longevity market deck, online search interest in longevity has been steadily increasing
Summary table of the latest funding deals in the longevity market as of June 2026
We define the longevity market as products and services that use science, medicine, or technology to extend healthy years of life and slow or improve the effects of aging.
We include therapies, diagnostics, clinics, digital tools, supplements, and programs that are explicitly designed and marketed to improve healthspan, prevent age-related decline, or optimize long-term health.
We exclude generic healthcare, wellness, beauty, fitness, eldercare, and financial products that serve older adults but are not specifically focused on longevity or healthspan.
You can also read our detailed analysis to understand how funding activity in the longevity market has evolved over the last few years.
We also have a quarter-by-quarter analysis of funding activity in the market here.
Finally, you can check our complete list of fundraising deals for the longevity market we update this list every quarter, as well as our ranking of the most funded startups.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| NewLimit | 2 to 3 June 2026 | $435.0M | Series C | Cellular rejuvenation therapeutics |
| Ultralight | 13 April 2026 | $9.3M | Seed | Longevity clinic infrastructure |
| Life Biosciences | 8 April 2026 | $80.0M | Series D | Partial epigenetic reprogramming therapeutics |
| HexemBio | 6 to 7 April 2026 | $10.4M | Seed | Stem-cell rejuvenation therapeutics |
| TMRW | 13 March 2026 | $7.0M | Seed | Longevity clinics & Diagnostics |
| Loyal | 11 February 2026 | $100.0M | Series C | Canine longevity drugs |
| Biopeak | 29 to 31 January 2026 | $2.7M | Follow-on | Healthy-aging clinics |
| L-Nutra | 21 January 2026 | $36.5M | Series D investment | Longevity nutrition |
| GlycanAge | 18 December 2025 | $8.7M | Funding round | Biological-age diagnostics |
| Decode Age | 17 December 2025 | $1.7M | Pre-Series A | Longevity diagnostics & Supplements |
| Aeovian Pharmaceuticals | 16 December 2025 | $55.0M | Series B | mTORC1 longevity therapeutics |
| Junevity | 3 December 2025 | $10.0M | Seed extension | Cellular reprogramming therapeutics |
All the latest funding deals during in the longevity market as of June 2026
NewLimit raised $435M in June 2026.
When was it?
The NewLimit Series C was announced on 2 June or 3 June 2026, depending on the publication date.
Who are they?
NewLimit develops epigenetic reprogramming medicines designed to restore youthful function in old cells.
Geographical focus?
NewLimit is a US biotech company with a global therapeutics opportunity.
Why do we include them in the longevity market?
NewLimit belongs in the longevity market because cellular reprogramming and age-reversal biology are central to its drug platform.
What is the company stage?
NewLimit is in a clinical-enabling and late-preclinical stage, with a lead liver candidate and a planned Phase 1 trial.
How much did they raise?
NewLimit raised $435.0M for this round, with a reported valuation around $3.1B.
What round is it?
The NewLimit financing was a Series C round.
Why did they raise?
NewLimit raised to move a lead reprogramming candidate toward human trials and expand programs across liver, vascular, and immune-cell biology.
Ultralight raised $9.3M in April 2026.
When was it?
The Ultralight funding was announced on 13 April 2026.
Who are they?
Ultralight builds an AI-native EHR and operating system for preventive, functional, integrative, and longevity medicine clinics.
Geographical focus?
Ultralight mainly focuses on US clinics serving preventive and personalized medicine patients.
Why do we include them in the longevity market?
Ultralight belongs in the longevity market because its software infrastructure is built for longevity and personalized preventive medicine practices.
What is the company stage?
Ultralight is in early product-market fit, with the product live in dozens of clinics and a Series A planned for 2027.
How much did they raise?
Ultralight raised $9.3M for this round.
What round is it?
The Ultralight financing combined pre-seed and seed funding.
Why did they raise?
Ultralight raised to replace fragmented clinic software with one AI-native system and scale clinical intelligence, protocols, and sales.
This chart, featured in our longevity market deck, compares the main business model options for longevity clinics
Life Biosciences raised $80M in April 2026.
When was it?
The Life Biosciences Series D was announced on 8 April 2026.
Who are they?
Life Biosciences develops partial epigenetic reprogramming therapies for diseases linked to aging.
Geographical focus?
Life Biosciences is a US biotech company with a global therapeutics opportunity.
Why do we include them in the longevity market?
Life Biosciences belongs in the longevity market because the company works on cellular rejuvenation and age-related disease reversal.
What is the company stage?
Life Biosciences is a clinical-stage company, with financing supporting a Phase 1 trial of ER-100.
How much did they raise?
Life Biosciences raised $80.0M for this round.
What round is it?
The Life Biosciences financing was a Series D round.
Why did they raise?
Life Biosciences raised to fund the ER-100 Phase 1 trial in optic neuropathies and continue building its partial reprogramming pipeline.
HexemBio raised $10.4M in April 2026.
When was it?
The HexemBio seed round was announced on 6 April or 7 April 2026.
Who are they?
HexemBio develops ex vivo blood stem-cell rejuvenation technology designed to restore aging-related immune function.
Geographical focus?
HexemBio focuses on North American biotech markets first, with global therapeutics potential.
Why do we include them in the longevity market?
HexemBio belongs in the longevity market because the company targets age-related immune decline through stem-cell rejuvenation.
What is the company stage?
HexemBio is preclinical and moving toward IND-enabling studies and manufacturing scale-up.
How much did they raise?
HexemBio raised $10.4M for this round.
What round is it?
The HexemBio financing was a seed round.
Why did they raise?
HexemBio raised to advance its rejuvenated blood stem-cell platform toward IND-enabling work and scalable manufacturing.
This chart, featured in our longevity market deck, looks at Function Health’s strategy in longevity
TMRW raised about $7M in March 2026.
When was it?
The TMRW seed round was announced on 13 March 2026.
Who are they?
TMRW runs a longevity membership clinic model using diagnostics, biomarkers, epigenetic age testing, and clinical support.
Geographical focus?
TMRW focuses on Australia.
Why do we include them in the longevity market?
TMRW belongs in the longevity market because its clinical product is built around healthspan measurement and longevity optimization.
What is the company stage?
TMRW is in early product-market fit, with an operating clinic model and expansion plans.
How much did they raise?
TMRW raised about $7.0M for this round.
What round is it?
The TMRW financing was a seed round.
Why did they raise?
TMRW raised to expand clinics and improve the longevity patient experience.
Loyal raised $100M in February 2026.
When was it?
The Loyal Series C was announced on 11 February 2026.
Who are they?
Loyal develops FDA-regulated drugs intended to extend healthy lifespan in dogs.
Geographical focus?
Loyal focuses on the US pet therapeutics market first, with broader animal-health potential.
Why do we include them in the longevity market?
Loyal belongs in the longevity market because the company is directly developing lifespan-extension drugs, starting with dogs.
What is the company stage?
Loyal is clinical-stage and market-readiness focused, with LOY-002 moving toward FDA review and commercial launch.
How much did they raise?
Loyal raised $100.0M for this round.
What round is it?
The Loyal financing was a Series C round.
Why did they raise?
Loyal raised to finish regulatory work, keep investing in its science platform, expand the team, and prepare for commercial launch.
In our longevity market deck, we identify pain points entrepreneurs should prioritize
Biopeak raised $2.7M in January 2026.
When was it?
The Biopeak follow-on round was announced between 29 January and 31 January 2026.
Who are they?
Biopeak runs an AI-driven longevity and health-optimization clinic model using diagnostics, biomarker tracking, and personalized interventions.
Geographical focus?
Biopeak focuses on India, starting in Bengaluru.
Why do we include them in the longevity market?
Biopeak belongs in the longevity market because its core product is a longevity clinic and health-optimization program.
What is the company stage?
Biopeak is in early growth, with one Bengaluru clinic open and another clinic planned.
How much did they raise?
Biopeak raised $2.7M for this round.
What round is it?
The Biopeak financing was a follow-on round.
Why did they raise?
Biopeak raised to open another clinic, upgrade diagnostics, build proprietary AI tools, and expand research and clinical programs.
L-Nutra raised $36.5M in January 2026.
When was it?
The L-Nutra Series D investment was announced on 21 January 2026.
Who are they?
L-Nutra develops fasting-mimicking and medical nutrition programs designed for longevity, healthspan, and chronic disease remission.
Geographical focus?
L-Nutra has a global focus, with a new MENA expansion push through Abu Dhabi.
Why do we include them in the longevity market?
L-Nutra belongs in the longevity market because its products are marketed as science-driven longevity and medical nutrition therapies.
What is the company stage?
L-Nutra is growth-stage, with commercial products, clinical evidence, patents, and international expansion plans.
How much did they raise?
L-Nutra raised $36.5M for this investment, bringing Series D proceeds to $83.5M.
What round is it?
The L-Nutra financing was part of its Series D round.
Why did they raise?
L-Nutra raised to accelerate global expansion and create an Abu Dhabi joint venture for MENA longevity and medical nutrition products.
This market map, featured in our longevity market deck, highlights top companies and startups in the longevity market
GlycanAge raised about $8.7M in December 2025.
When was it?
The GlycanAge funding round was announced on 18 December 2025.
Who are they?
GlycanAge measures biological age and inflammaging through IgG glycan biomarkers used in preventive and healthy-aging care.
Geographical focus?
GlycanAge has roots in the UK and Europe, with a broader push to reach clinicians globally.
Why do we include them in the longevity market?
GlycanAge belongs in the longevity market because biological-age measurement helps track aging, inflammation, and healthspan interventions.
What is the company stage?
GlycanAge is in early growth, expanding from clinics into more clinical and preventive-care settings.
How much did they raise?
GlycanAge raised about $8.7M for this round.
What round is it?
The GlycanAge financing was a funding round led by Fifth Quarter Ventures.
Why did they raise?
GlycanAge raised to accelerate clinical development of glycan diagnostics and expand clinician access worldwide.
Decode Age raised $1.7M in December 2025.
When was it?
The Decode Age Pre-Series A round was announced on 17 December 2025.
Who are they?
Decode Age builds longevity diagnostics, biomarker tools, gut microbiome analytics, and supplements focused on aging biology.
Geographical focus?
Decode Age focuses on India.
Why do we include them in the longevity market?
Decode Age belongs in the longevity market because the company combines aging biomarkers, microbiome science, and products focused on aging biology.
What is the company stage?
Decode Age is in early product-market fit and is expanding research, analytics, and commercial products.
How much did they raise?
Decode Age raised about $1.7M for this round.
What round is it?
The Decode Age financing was a Pre-Series A round.
Why did they raise?
Decode Age raised to expand biomarker discovery, multi-omics research, microbiome research, and analytics infrastructure.
This chart, featured in our longevity market deck, illustrates yearly funding for longevity startups
Aeovian Pharmaceuticals raised $55M in December 2025.
When was it?
The Aeovian Pharmaceuticals Series B was announced on 16 December 2025.
Who are they?
Aeovian Pharmaceuticals develops selective mTORC1 inhibitors designed to restore cellular metabolic quality control in age-related disease biology.
Geographical focus?
Aeovian Pharmaceuticals is a US biotech company with a global drug-market opportunity.
Why do we include them in the longevity market?
Aeovian Pharmaceuticals belongs in the longevity market because mTOR biology is a central pathway in aging and age-related disease.
What is the company stage?
Aeovian Pharmaceuticals is clinical-stage, with the financing supporting Phase 2 proof-of-concept work.
How much did they raise?
Aeovian Pharmaceuticals raised $55.0M for this round.
What round is it?
The Aeovian Pharmaceuticals financing was a Series B round.
Why did they raise?
Aeovian Pharmaceuticals raised to complete Phase 2 proof-of-concept work for AV078 and advance its mTORC1 therapeutic pipeline.
Junevity raised $10M in December 2025.
When was it?
The Junevity seed extension was announced on 3 December 2025.
Who are they?
Junevity develops siRNA cell-reprogramming therapeutics intended to reset age-related cellular dysfunction.
Geographical focus?
Junevity is a US biotech company with a global therapeutic opportunity.
Why do we include them in the longevity market?
Junevity belongs in the longevity market because its mission is lifespan and healthspan extension through cell reprogramming.
What is the company stage?
Junevity is preclinical and working toward first-in-human studies for JUN_01.
How much did they raise?
Junevity raised $10.0M in new funding, expanding its seed financing to $20.0M.
What round is it?
The Junevity financing was a seed extension.
Why did they raise?
Junevity raised to advance JUN_01 for type 2 diabetes and obesity through IND-enabling work and initial clinical studies.
Related blog posts
- How strong is fundraising in the longevity market right now?
- The most recent news in the longevity market
- How large is the longevity market in reality?
- The evolution of funding activity in the longevity market
- The main fundraising trends in the longevity market
- All the recent funding deals in the longevity market
- The startups that have raised the most funding in the longevity market
- The most highly valued startups in the longevity market
